Search results
Treatment of Bifurcation Coronary Artery Disease with the Dedicated Cappella Sideguard® Stent
Author(s):
Mamas A Mamas
,
Farzin Fath-Ordoubadi
Added:
3 years ago
Article
Author(s):
Shao-Liang Chen
,
Imad Sheiban
Added:
3 years ago
Bifurcation lesions account for approximately 20–30% of all percutaneous coronary interventions (PCIs). Coronary bifurcation sites are prone to developing obstructive atherosclerotic disease due to turbulent blood flow and change of shear stress. With the complexity of bifurcation lesions, several classification systems have been advocated in order to extablish percutaneous strategies.1–3 In fact…
View more
Author(s):
Jacek Bil
,
Robert Gil
,
Dobrin Vassilev
Added:
8 years ago
Dedicated Bifurcation Drug-eluting Stent BiOSS® – A Novel Device for Coronary Bifurcation Treatment
Author(s):
Robert Gil
,
Dobrin Vassilev
,
Jacek Bil
Added:
3 years ago
Article
Author(s):
Helen Routledge
Added:
3 years ago
The preferred treatment approach for bifurcation disease can be generally summed up as ‘keep it simple’, otherwise known as provisional stenting. Based on several contemporary studies, coronary interventionalists have settled on a minimalist approach: starting with a single-stent approach for the main vessel (MV) and ignoring side branch (SB) disease unless clinical circumstances warrant…
View more
Author(s):
Nicolas Foin
,
Eduardo Alegria-Barrero
,
Ryo Torii
,
et al
Added:
3 years ago
Drug-eluting stents (DESs) have contributed to a significant lowering of the incidence of restenosis and target vessel revascularisation (TVR) in bifurcations.1–4 A randomised study of bifurcation lesions using sirolimus-eluting stents revealed restenosis rates of only 4 % in the main branch (MB) and a TVR rate as low as 8.2 % at six-month follow-up,2 a marked improvement over that in historical…
View more